Pennsylvania is currently home to 3317 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Reduction of Adverse Drug Events and Readmissions
NCT02738047
Recruiting
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
Gender:
ALL
Ages:
25 years and above
Trial Updated:
02/06/2024
Locations: MD@Home, York, Pennsylvania
Conditions: Pharmacogenomic Testing for Medication Management
Register for Updates
The Impact of Retropubic Lidocaine vs Saline on Postoperative Urinary Retention Following Midurethral Sling
NCT03913845
Recruiting
Stress urinary incontinence affects millions of women worldwide and has a profound impact on the quality of life of older individuals, their subjective health status, levels of depression and need for care. Midurethral sling placement was introduced in 1995 and remains the current gold standard for surgical management of SUI. Although the advantages of midurethral sling surgery include its high success and minimally invasive approach, approximately 10-50% of women experience acute postoperative... Read More
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
02/05/2024
Locations: AHN Bethel Park Health + Wellness Pavilion, Bethel Park, Pennsylvania
Conditions: Stress Urinary Incontinence
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates
The Acute Burn ResUscitation Multicenter Prospective Trial
NCT04356859
Recruiting
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: Burn Injury
Register for Updates
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03190278
Recruiting
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Register for Updates
A Study of AT-02 in Subjects With Systemic Amyloidosis.
NCT05951049
Recruiting
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/29/2024
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Amyloidosis; Systemic
Register for Updates
LE as a Marker for Periprosthetic Joint Infection
NCT05440032
Recruiting
Testing and comparison of a novel point-of-care electrochemical assay to detect and help diagnose periprosthetic joint infection on the hip and knee to the standard of care test
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Rothman Orthopaedic Institute, Philadelphia, Pennsylvania
Conditions: Prosthetic-joint Infection
Register for Updates
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
NCT04296864
Recruiting
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Vantage EyeCare, LLC., Bala-Cynwyd, Pennsylvania
Conditions: Atopic Keratoconjunctivitis
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh, Pennsylvania
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
mychoiceTM Implementation With Medical Oncology Patients
NCT06222242
Recruiting
This is a pragmatic, non-randomized mixed-methods evaluation study designed to evaluate the feasibility and acceptability of delivering the mychoiceTM tool to new Medical Oncology patients as well as to more deeply explore its value to patients in their discussion with their provider about clinical trials as a treatment option over the course of their oncology treatment (Effectiveness).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Outcomes of Functional Substrate Mapping of Ventricular Tachycardia
NCT05708131
Recruiting
The goal of this registry database is to demonstrate the safety and effectiveness of functional ventricular tachycardia (VT) ablation using SENSE protocol in patients with ischaemic VT. Mortality and the need for ICD therapies at 12 months post-ablation will be compared with propensity-matched controls undergoing substrate-based ablation alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ventricular Tachycardia
Register for Updates